Ihab G. Girgis

TL;DR: Selective inhibition of TYK2 with the oral agent BMS‐986165 at doses of 3 mg daily and higher resulted in greater clearing of psoriasis than did placebo over a period of 12 weeks.

TL;DR: In this first clinical evaluation of programmed cell death protein-1/programmed cell death-ligand 1 pathway inhibition in sepsis, BMS-936559 was well tolerated, with no evidence of drug-induced hypercytokinemia or cytokine storm, and at higher doses, some indication of restored immune status over 28 days.

TL;DR: In this sepsis population, nivolumab administration did not result in unexpected safety findings or indicate any ‘cytokine storm’, and the PK profile maintained RO’> 90% for 28 days post-infusion.

TL;DR: Deucravacitinib, a novel, oral, selective inhibitor of tyrosine kinase 2 (TYK2) signaling, acts via an allosteric mechanism by binding to the enzyme's regulatory domain instead of the catalytic domain this paper.

TL;DR: This study evaluated safety, pharmacokinetics and pharmacodynamics of branebrutinib in healthy participants.